- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07599098
Effects of a Pilates Studio Program on Quality of Life and Functional Capacity of Women Undergoing Breast Cancer Treatment (Cancer)
Effects of a Pilates Studio Program on Quality of Life, Functional Capacity, Pain, Fatigue, Sarcopenia, Flexibility, Strength, Body Composition, Self-Esteem, Anxiety and Depression in Women Undergoing Breast Cancer Treatment
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Andréa D Reis Dra., Teacher
- Phone Number: 98987220570
- Email: andrea.dr@ufma.br
Study Contact Backup
- Name: Hyrllanny P Santos Hyrllanny Pereira dos Santos, Student
- Phone Number: 98988359435
- Email: hyrllanny.santos@discente.ufma.br
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Women aged 18 or older;
- Being under treatment for breast cancer (chemotherapy, radiotherapy, immunotherapy and/or hormone therapy);
- No previous neurological/musculoskeletal disorders that impede active movement;
- No recent surgeries.
Exclusion Criteria:
- Patients with problems secondary to breast cancer that limit active movement;
- Presence of inflammation or edema in the abdomen, groin, and upper and lower extremities;
- Having another type of cancer;
- Having a cognitive impairment or injury that prevents them from performing physical assessments or completing questionnaires.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Pilates Studio Programming Group
The intervention will consist of 16 weeks of in-person Pilates studio classes, three times a week in the mornings, lasting 60 minutes each, totaling 48 sessions.
|
There will be 16 weeks of intervention, with in-person Pilates studio classes three times a week, lasting 60 minutes each, in the morning, totaling 48 sessions. The classes will follow this order: Warm-up with initial stretches, lasting 10 minutes. This will be followed by the Pilates program lasting 40 minutes, and concluding with a 10-minute relaxation period. Every four weeks there will be a progression in intensity, with modifications to the exercises.
Other Names:
|
|
No Intervention: Control group
Participants in the Control Group will receive standard care.
They will not participate in the intervention, only answering questionnaires and performing tests during the initial assessment periods, after 4 weeks, 8 weeks, 12 weeks, and after 16 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain assessment
Time Frame: From registration to the end of treatment in 16 weeks
|
Pain will be assessed using the Brief Pain Inventory (BPI), a 10-point pain intensity scale ranging from 0 (no pain) to 10 (worst imaginable pain), developed specifically for patients with cancer-related pain.
In addition, the BPI provides information on how pain interferes with daily functioning in 7 areas: general activity, walking, mood, sleep, work, enjoyment of life, and social activity.
|
From registration to the end of treatment in 16 weeks
|
|
Fatigue
Time Frame: From registration to the end of treatment in 16 weeks
|
Fatigue will be measured using the Piper Fatigue Scale (PFS-P).
Fatigue is a relevant symptom for cancer patients, with a greater impact than in the general population.
It is described at all stages of the cancer patient's journey, presenting as physical, emotional, or cognitive exhaustion or weakness, which can interfere with daily function and chemotherapy treatment.
|
From registration to the end of treatment in 16 weeks
|
|
General quality of life evaluation
Time Frame: From enrollment to end of treatment in 16 weeks
|
The instrument used to assess Quality of life will be the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30).
The questions are using a numerical scale from 0 to 100 for scales.
In the functional and global scales the EORTC-BR 30, the higher scores mean a better quality of life and lower scores mean a worse quality of life.
Unlike, in the symptom scale EORTC-BR 30, the higher scores mean a worse quality of life and lower scores mean a better quality of life.
|
From enrollment to end of treatment in 16 weeks
|
|
Quality of life specifically for breast cancer
Time Frame: From registration to the end of treatment in 16 weeks
|
The instrument used to assess Quality of life specifically for breast cancer will be the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-BR).
The questions are using a numerical scale from 0 to 100 for scales.
In the functional scale the EORTC-BR 23, the higher scores mean a better quality of life and lower scores mean a worse quality of life.
Unlike, in the symptom scale the EORTC-BR 23, the higher scores mean a worse quality of life and lower scores mean a better quality of life.
|
From registration to the end of treatment in 16 weeks
|
|
Sarcopenia
Time Frame: From registration to the end of treatment in 16 weeks
|
Sarcopenia assessment will be performed using the SARC-F questionnaire.
The protocol includes five components: strength, assisted gait, rising from a chair, climbing stairs, and falls.
The SARC-F items were selected to reflect changes in health status associated with the consequences of sarcopenia.
SARC-F scale scores range from 0 to 10 (i.e., 0-2 points for each component; 0 = best to 10 = worst) and were dichotomized to represent symptomatic (4+) versus healthy (0-3) status.
Additionally, a modified version of the instrument, the SARC-Calf (SARC-F + CP), which integrates an anthropometric measure into the traditional score, was employed.
|
From registration to the end of treatment in 16 weeks
|
|
Functional capacity of upper limbs
Time Frame: From registration to the end of treatment in 16 weeks
|
The Back Scratch Test is part of the battery of physical fitness tests for older adults and is used to measure the flexibility and range of motion of the shoulder joint (scapular girdle).
The test consists of placing one hand on the same shoulder and the other hand underneath, attempting to touch or overlap the middle fingers of both hands on the back.
The distance between the fingers is measured, where positive values indicate overlap and negative values indicate the distance remaining for touch.
Test scores are classified as: negative (-): If the fingers do not touch (distance between them); zero (0): If the fingers only touch; positive (+): If the fingers overlap.
|
From registration to the end of treatment in 16 weeks
|
|
Functional capacity of the upper limbs
Time Frame: From registration to the end of treatment in 16 weeks
|
The Disabilities of the Arm, Shoulder, and Hand (DASH) questionnaire is a validated self-administered instrument for assessing symptoms and functional capacity in individuals with musculoskeletal disorders of the upper limbs. The questionnaire is validated for Brazilian Portuguese and consists of 30 items that assess an individual's ability to perform certain physical activities (21 items), the severity of symptoms such as pain, tingling, and weakness (5 items), and the impact of upper limb function on social life, work, sleep, and self-confidence (4 items). Each item is scored on a scale of 1 to 5. DASH score = ({Sum of responses}/{n} - 1 ) x 25. Where n is the number of questions answered. The score ranges from 0 to 100, where the higher the value, the greater the functional disability. |
From registration to the end of treatment in 16 weeks
|
|
Quality of life specifically for breast cancer
Time Frame: From registration to the end of treatment in 16 weeks
|
The instrument used to assess quality of life specifically in cases of breast cancer will be the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-BR).
The questions use a numerical scale from 0 to 100.
On the functional scale of the EORTC-BR-23, higher scores indicate better quality of life and lower scores indicate worse quality of life.
On the symptom scale of the EORTC-BR-23, higher scores indicate worse quality of life and lower scores indicate better quality of life.
|
From registration to the end of treatment in 16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Functional Capacity: 6-minute walk test
Time Frame: From registration to the end of treatment in 16 weeks
|
Functional capacity, or cardiorespiratory fitness, will be assessed using the 6-minute walk test performed in a 10-meter corridor.
The patient will be monitored during the test for safety.
|
From registration to the end of treatment in 16 weeks
|
|
Functional capacity: 6-minute step test
Time Frame: From registration to the end of treatment in 16 weeks
|
Functional capacity will be assessed using the 6-minute step test.
The test consists of repeatedly stepping up and down a step with a standardized height between 20 and 30 cm for a continuous period of six minutes, with the total number of cycles or steps completed being recorded at the end of the established time.
The patient will be monitored during the test for safety.
|
From registration to the end of treatment in 16 weeks
|
|
Functional independence
Time Frame: From registration to the end of treatment in 16 weeks
|
The Barthel Index is a widely used instrument to assess the degree of functional independence of individuals in performing basic activities of daily living.
Its score ranges from 0 to 100 points, distributed across ten dimensions that encompass tasks related to self-care and mobility.
It is a validated measure for Portuguese, with evidence of reliability and clinical applicability in different contexts of functional assessment.
|
From registration to the end of treatment in 16 weeks
|
|
General Flexibility
Time Frame: From registration to the end of treatment, in 16 weeks
|
For flexibility assessment, the Schober test was used, which determines functional flexibility and is more specific to the lumbar region.
It is a test with high specificity compared to the gold standard, radiography.
However, it is a quick and low-cost test, widely used in clinical practice.
The test evaluates lumbar movement restrictions through markings: on the lumbosacral joint (joining the posterior superior iliac spines) and 10 cm above; the distance between these markings is noted in an upright position.
Immediately after, the subject performs a maximum trunk flexion (lower limbs extended), and the evaluator measures the new distance between the points with a measuring tape and records the difference between the marks based on the patient's best reach score in relation to the ground.
|
From registration to the end of treatment, in 16 weeks
|
|
Upper limb strength
Time Frame: From registration to the end of treatment, in 16 weeks
|
Measuring handgrip strength using a dynamometer is a simple, objective, practical, and easy-to-use procedure.
Recommended by the American Society of Hand Therapists.
The instruction is to perform a maximum contraction for 3 seconds in each test.
A 30-second rest period is required between each test, and a 2-minute rest period is required between tests for each hand.
|
From registration to the end of treatment, in 16 weeks
|
|
Lower limb strength
Time Frame: From registration to the end of treatment, in 16 weeks
|
The 30-Second Chair Stand Test is widely used to assess lower limb strength and muscle endurance in clinical and elderly populations.
The protocol requires the participant to stand from a chair and sit down as many times as possible within 30 seconds, without using their hands.
Performance on this test is a strong predictor of functional autonomy and is directly related to screening for sarcopenia risk.
Classification varies according to age and conditioning achieved during the test, defined as: Disability Risk: >8 repetitions for women are considered predictors of high risk of falls and loss of autonomy; Cutoff Point for Sarcopenia: >15 repetitions is an indicator of reduced muscle quality.
|
From registration to the end of treatment, in 16 weeks
|
|
Muscle Mass
Time Frame: From registration to the end of treatment, in 16 weeks.
|
It will be measured using Bioelectrical Impedance Analysis (BIA), a widely used method that estimates muscle mass by measuring the body's resistance and reactance to the passage of a low-intensity electrical current, and is low-cost, easy to apply, and portable.
|
From registration to the end of treatment, in 16 weeks.
|
|
Self-esteem
Time Frame: From registration to the end of treatment in 16 weeks
|
To assess self-esteem, the Portuguese version adapted and validated by Hutz of the Rosenberg Self-Esteem Scale will be used.
The total score ranges from 10 to 40 points.
Higher scores indicate better self-esteem and lower scores indicate worse self-esteem.
|
From registration to the end of treatment in 16 weeks
|
|
Anxiety and Depression
Time Frame: From registration to the end of treatment, in 16 weeks.
|
Anxiety and depression will be assessed using the Hospital Anxiety and Depression Scale (HADS) questionnaire.
The total score ranges from 0 to 21 points.
The cut-off points adopted will be: an anxiety score of 8 or higher; and a depression score of 9 or higher.
|
From registration to the end of treatment, in 16 weeks.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Andrea Dias Reis, Teacher, Federal University of Maranhão, São Luís, Maranhão, Brazil
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CAAE: 88530425.5.0000.5087
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Colorado, DenverCompletedStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast CancerUnited States
-
National Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerCanada
-
Mayo ClinicMarker Therapeutics, Inc.CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
Clinical Trials on Pilates Studio Program Group
-
Riphah International UniversityCompleted
-
Riphah International UniversityCompletedSports Physical TherapyPakistan
-
Hacettepe UniversityCompleted
-
João Luiz Q. DuriganCatholic University of BrasíliaCompleted
-
Batman UniversityCompletedMenopausal | Obese Patients | Quality of Life and Menopause | Pilates ExerciseTurkey
-
Recep Tayyip Erdogan University Training and Research...CompletedDepression | Epilepsy | Quality of Life | Sleep | Cognitive Dysfunction | SeizuresTurkey
-
Universidade Cidade de Sao PauloActive, not recruiting
-
Aristotle University Of ThessalonikiCompleted
-
Federal University of ParaíbaCompletedChronic Low Back Pain | Nonspecific Chronic Low Back Pain
-
Universidade Cruzeiro do SulCompletedLower Back PainBrazil